GlassScriptPhysician profile
Donna B Rackley
NPI 1801873583
$6,333.50
in general payments reported to CMS, 2019-2025
27 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.81 · 2022: $1,106 · 2023: $2,723 · 2024: $1,098 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,190.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,634.41 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $613.06 | 2022-2025 | Spravato |
| Axsome Therapeutics, INC. | $504.97 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.67 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $380.79 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $355.08 | 2022-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $346.42 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $286.00 | 2022-2023 | Austedo, Austedo Xr |
| Lundbeck LLC | $240.41 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $237.23 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $209.28 | 2022-2023 | Qelbree |
| Idorsia Pharmaceuticals US INC | $183.97 | 2022-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $142.57 | 2025 | Cobenfy |
| Corium, LLC | $128.89 | 2022-2023 | Azstarys |
| Neos Therapeutics, LP | $125.25 | 2022-2023 | Adzenys Xr-Odt |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $83.25 | 2022 | |
| Bausch Health US, LLC | $79.03 | 2022-2025 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $75.70 | 2022-2023 | Belsomra |
| Almatica Pharma LLC | $56.90 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $45.40 | 2022-2023 | Trintellix |
| Brainsway USA INC | $39.12 | 2023-2025 | Deep Tms System |
| Biogen, INC. | $22.51 | 2024 | |
| Jazz Pharmaceuticals INC. | $22.39 | 2021 | |
| Eisai INC. | $19.50 | 2022 | |
| Tris Pharma INC | $19.29 | 2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $16.11 | 2022 | |
| Acadia Pharmaceuticals INC | $13.30 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Rackley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.